Scarica l'app Stockscreener
18.27
255.45%
13.13
Dopo l'orario di chiusura:
13.25
-5.02
-27.48%
Precedente Chiudi:
$5.14
Aprire:
$9.92
Volume 24 ore:
33.47M
Relative Volume:
61.65
Capitalizzazione di mercato:
$20.91M
Reddito:
-
Utile/perdita netta:
$-17.27M
Rapporto P/E:
-1.7631
EPS:
-10.3626
Flusso di cassa netto:
$-10.59M
1 W Prestazione:
+423.50%
1M Prestazione:
+215.54%
6M Prestazione:
+1.50%
1 anno Prestazione:
-63.60%
Intervallo 1D:
$8.58
$18.99
Intervallo di 1 settimana:
$3.15
$18.99
Portata 52W:
$3.015
$56.80
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(929) 274-7510
Indirizzo
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
18.27 | 5.88M | 0 | -17.27M | -10.59M | -10.36 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Downgrade | Maxim Group | Buy → Hold |
| 2026-01-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-07-18 | Iniziato | Maxim Group | Buy |
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics (AKTX) AGM June 30, 2026 — equity authorizations, warrants/ADSs - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) sets $5.5M ADS and warrant private placement - Stock Titan
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
Discover the top movers in Friday's pre-market session. - ChartMill
Akari Therapeutics Announces $5.5 Million Private Placement Offering - Sahm
Akari Therapeutics stock rockets 50% higher on KRAS combination data - Investing.com
Akari Therapeutics prices $5.5 million private placement By Investing.com - Investing.com South Africa
Akari Therapeutics prices $5.5 million private placement - Investing.com
Why Akari Therapeutics Stock Is Surging On Thursday? - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Akari Therapeutics secures European patent for ADC payload - Investing.com
[S-1] Akari Therapeutics Plc Files IPO Registration Statement - Stock Titan
Debt to equity ratio of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
AKTX - Finviz
Akari Therapeutics secures Australian patent for ADC payload By Investing.com - Investing.com South Africa
Akari Therapeutics secures Australian patent for ADC payload - Investing.com India
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors - ChartMill
Maxim Sees High Risk Profile for Akari Therapeutics, plc (AKTX) Amid Capital Needs - Insider Monkey
Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing - ChartMill
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Akari Therapeutics PLC (FRA:CLA1) Stock Price, Trades & News - GuruFocus
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - ChartMill
Total equity of Akari Therapeutics Plc Sponsored ADR – LSX:A4270Y - TradingView — Track All Markets
Long term debt to total assets ratio of Akari Therapeutics Plc Sponsored ADR – FWB:CLA1 - TradingView
Discontinued operations of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Akari Therapeutics partners with WuXi XDC on ADC development By Investing.com - Investing.com India
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Who's Buying or Selling Akari Therapeutics PLC (FRA:CLA1) Stock Today? - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC (FRA:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics PLC Stock Baskets | FRA:CLA1 - GuruFocus
Akari Therapeutics PLC Stock Operating Data - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Valuation - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC Stock Baskets | STU:CLA1 - GuruFocus
Akari Therapeutics PLC (STU:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics ADR: Dividend historical data and projections - marketscreener.com
Akari Therapeutics ADR: Revenue and Earnings Analysts Forecasts Revisions | AKTX | US00972G4055 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) sets ADS ratio to 1:80,000 in F-6/A filing - Stock Titan
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) outlines ADC oncology strategy - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Declines By 19.4% - Defense World
Akari Therapeutics revises ADS ratio to maintain Nasdaq compliance - MSN
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Akari Therapeutics Announces ADS Ratio Change, Reverse Split - The Globe and Mail
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):